Fundraising Fox

Axonis Therapeutics

Boston, US · Founded 2019 · Delaware corporation · 27 employees on LinkedIn · 14 known investors

Find your way into Axonis Therapeutics

566 people in our graph share verified history with the Axonis Therapeutics team — schools, employers, funds. One of them is your warm intro.

Logan Hilleunlockedknows Shane V. Hegarty · together at Harvard Medical School (overlapped)
×4knows the team · via Boston Children's Hospital
×3knows the team · via Creative Destruction Lab
knows the team · via On Deck
×3knows the team · via Harvard Medical School

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain. It translates discoveries from Boston Children's Hospital, Harvard and Laval University into central nervous system therapies.

BiotechDeep Tech

Founders & leadership

Axonis Therapeutics was founded in 2019 by Shane V. Hegarty.

SVShane V. Hegarty
Shane V. HegartyinChief Scientific Officer & Co-FounderShane Hegarty holds a BSc in neuroscience from University College Cork and earned postdoctoral fellowships from the Irish Research Council and National University of Ireland. He held a tenure-track lecturer position in neuroscience at UCC before joining Boston Children's Hospital and Harvard as a research fellow in the laboratory of Zhigang He, where his research on neurological mechanisms led to the founding of Axonis Therapeutics.
JSJoanna Stanicka
Joanna StanickainChief Executive Officer
JIJeff Imbaro
Jeff ImbaroinChief Operating Officer
TSTiasha Shafiq
Tiasha ShafiqinChief of Staff

Board

C.
Corey . GoodmaninBoard directorGeneral Partner at venBio Global Strategic
JLJonathan Leff
Jonathan LeffinBoard MemberExecutive Partner, Private Equity at Sofinnova Ventures
RJ
Raymond J. KelleherBoard director
DM
Donald Manning, M.D., Ph.Dr
BR
Brock ReeveBoard director

Investors · 14

venBio Partners✓ verifiedSan Francisco
MRL Ventures Fund✓ verifiedCambridge · $25M
Sofinnova Ventures✓ verifiedMenlo Park · $100K – $15M
Civilization Ventures Management, LlcTiburon · $1M – $10M
Creative Destruction Lab (CDL)Toronto · $50K – $250K
Hatteras Venture PartnersResearch Triangle · $500K – $4M
Iaso VenturesCambridge
Lumira VenturesToronto · $1M – $10M
Pathway BioventuresChicago
SCI VenturesLondon
Solasta VenturesBoston
Tachyon VenturesLos Angeles
BoxOne VenturesreportedMontréal · $500K
venBio Global StrategicreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$46M disclosed across 1 round · 2024

▶$46MraisedNov 2024 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Donald Manning, M.D., Ph.DExecutive Officer
  • Jeffrey ImbaroExecutive Officer
  • Corey . GoodmanDirector
  • Brock ReeveDirector
  • Shane HegartyExecutive Officer
  • Joanna StanickaExecutive Officer, Director
  • Jonathan LeffDirector
  • Raymond J. KelleherDirector
Offering amount
$115M
Amount sold
$46M
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld23 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Axonis Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 5 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$299.8K
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2.2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$335.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$298.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$330.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Business Post (@businessposthq) on Xx.com · Oct 2024Axonis Therapeutics bags $115m for neuromedicine developmentsiliconrepublic.com · Oct 2024Axonis Therapeutics gets $115 million to treat paincen.acs.org · Oct 2024With $115 million, biotech startup Axonis Therapeutics pivots to burgeoning pain fieldstatnews.com · Oct 2024Axonis Therapeutics Raises $115M in Series A Financing to Advance Novel Neuromedicines | Venture Capitalventurecapital.com · Oct 2024Axonis Therapeutics Raises $115M in Series A Financingfinsmes.com · Oct 2024

Frequently asked questions

What does Axonis Therapeutics do?
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain. It translates discoveries from Boston Children's Hospital, Harvard and Laval University into central nervous system therapies.
Who founded Axonis Therapeutics?
Axonis Therapeutics was founded by Shane V. Hegarty in 2019.
Who are Axonis Therapeutics's investors?
Axonis Therapeutics's investors include venBio Partners, MRL Ventures Fund, Sofinnova Ventures, Civilization Ventures Management, Llc, Creative Destruction Lab (CDL), Hatteras Venture Partners, Iaso Ventures, Lumira Ventures and 6 more.
How much funding has Axonis Therapeutics raised?
Axonis Therapeutics has disclosed $46M raised across 1 round.
Where is Axonis Therapeutics headquartered?
Axonis Therapeutics is headquartered in Boston, US.